Epoetin Alfa Treatment Results in Clinically Significant Improvements in Quality of Life in Anemic Cancer Patients When Referenced to the General Population

2003 ◽  
Vol 21 (2) ◽  
pp. 366-373 ◽  
Author(s):  
David Cella ◽  
Martin J. Zagari ◽  
Christina Vandoros ◽  
Dennis D. Gagnon ◽  
Hans-Jürgen Hurtz ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Trial ◽  
Clinical Trials ◽  
Cancer Patients ◽  
The United States ◽  
Internet Survey ◽  
Epoetin Alfa ◽  
Clinical Trial Results ◽  
Population Norm

Purpose: Anemia, highly common among cancer patients, is often an underlying cause of cancer-related fatigue and other quality-of-life (QOL) deficits. Although randomized clinical trials have shown that treatment with epoetin alfa increases hemoglobin levels, reduces fatigue, lessens transfusion requirements, and improves overall QOL, cancer-related anemia and fatigue remain undertreated. This is, in part, because scales and measures of QOL are still relatively unfamiliar to most clinicians and because population-based reference ranges are lacking, thus making clinical trial results difficult to interpret. Methods: To aid in the interpretation of QOL results from clinical trials, we administered the Functional Assessment of Cancer Therapy–Anemia (FACT-An) QOL instrument to a nationally representative sample of 1,400 people using an Internet survey panel in the United States. We then compared the FACT-An data from the Internet survey with the QOL data of a 375-patient randomized, double-blind clinical trial evaluating epoetin alfa versus placebo in anemic cancer patients. Results: FACT-An, as administered to the survey population, displayed good psychometric properties and was able to discriminate between respondents with histories of specified illnesses, including anemia and cancer, and those without. Comparison of the population norm and clinical trial data showed that treatment with epoetin alfa resulted in clinically meaningful as well as statistically significant improvements in QOL (P < .01). Conclusion: Reliable population norm data are now available to aid in the interpretation of clinical trial results where the FACT-An questionnaire is administered. In the clinical trial, treatment with epoetin alfa overcame much of the QOL deficit seen in anemic cancer patients compared with the norm population sample.

The Effect of Epoetin alfa on Quality of Life in Anemic Cancer Patients

1999 ◽  
Vol 7 (4) ◽  
pp. 177-182 ◽  
Author(s):  
David Cella ◽  
Dominique Bron
Keyword(s):  
Quality Of Life ◽  
Cancer Patients ◽  
Epoetin Alfa

A Clinical Trial of Cognitive Behavior Therapy for Psychiatric Comorbidity and Quality of Life with Cancer Patients during Chemotherapy (CPdC)

2021 ◽  
Author(s):  
Qasir Abbas ◽  
Nimra Arooj ◽  
Khawer Bilal Baig ◽  
Muhammad Umer Khan ◽  
Muhammad Khalid ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Trial ◽  
Psychological Distress ◽  
Cancer Patients ◽  
Death Anxiety ◽  
Satisfaction With Life ◽  
Psychiatric Symptoms ◽  
Self Esteem ◽  
Mean Difference

Abstract BackgroundCancer is a worldwide common illness, it evokes psychological distress at different stages, during chemotherapy patient perceives a variety of psychiatric symptoms due to various medication side-effects and psychological distress. Studies have shown a significant impact of CBT in the management of psychiatric symptoms during chemotherapy. This study aims to investigate the effectiveness of CBT for depression, anxiety, stress, death anxiety, satisfaction with life, and self-esteem among cancer patients during chemotherapy (CPdC).MethodsPlace and duration of the study: Department of Applied Psychology, Government College University Faisalabad in collaboration with Department of Oncology, Allied Hospital Faisalabad from November 20, 2020 and July 31, 2021. A total of 90 cancer patients were enrolled. 70 out of 90 met the eligibility criteria and 60 participants fulfilled all requirements. Participants were randomly allocated to four different groups. The pre-assessment screening was started along with the first trial of chemotherapy. The CBT-based treatment plan was formulated and one session per week was given to each patient for 3 to 4months. Participants’ age range was 18–65 years (M ± SD = 47.51 ± 12.36. Demographic form, DASS, DAS, SWLS, and RSES measures were used. Descriptive, t-test, and repeated measure ANOVA statistics were used to investigate the findings.ResultsResults indicated significant mean difference on the variable of depression, anxiety and stress across four conditions (i.e. F (2, 56) = 39.55, p < .000, η2 = .679; F(2,56) = 73.32, p < .000, η2 = .797; F(2,56) = 119.77, p < .000, η2 = .865 respectively). On death anxiety significant difference across four conditions was found (F (2,56) = 22.71, p < .000, η2 = .549) with large effect size. Furthermore, findings indicated significant mean difference on the variable of satisfaction with life and self-esteem across four conditions was found (F(2,56) = 22.05, p < .000, η2 = .542; F(2,56) = 36.19, p < .000, η2 = .660) with large effect size.ConclusionIt is concluded that CBT played a very effective role to reduce depression, anxiety, and stress-related psychiatric symptoms. CBT reduces the level of death anxiety and improving the quality of life and level of self-esteem among CPdC.Trial Registration: The study trial was registered in the Thai Clinical Trial Registry-TCTR (TCTR20201113002).

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.

1997 ◽  
Vol 15 (3) ◽  
pp. 1218-1234 ◽  
Author(s):  
J Glaspy ◽  
R Bukowski ◽  
D Steinberg ◽  
C Taylor ◽  
S Tchekmedyian ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Functional Status ◽  
Cancer Patients ◽  
Hemoglobin Level ◽  
Activity Level ◽  
Epoetin Alfa ◽  
Open Label ◽  
Transfusion Requirements ◽  
The Impact

PURPOSE To study the impact of Procrit (epoetin alfa; Amgen Inc, Thousand Oaks, CA) on quality of life, transfusion requirements, and hemoglobin in anemic cancer patients receiving chemotherapy. PATIENTS AND METHODS More than 500 community-based oncologists enrolled 2,342 patients with malignancies undergoing cytotoxic chemotherapy in an open-label study. Patients were treated with epoetin alfa 150 U/kg three times weekly, which could be doubled if the therapuetic response was judged inadequate. Total treatment was up to 4 months. RESULTS Of the 2,342 patients enrolled, data were available for 2,030 patients. Of the 2,030, 1,047 patients completed all 4 months of epoetin alfa therapy. Epoetin alfa was associated with significant increases in mean self-rated scores for energy level, activity level, and overall quality of life; these improvements correlated with the magnitude of the hemoglobin increase and were independent of tumor response. In addition, epoetin alfa was associated with a significant increase in mean hemoglobin and with a significant decrease in the proportion of patients requiring transfusions (baseline to final value, P < .001). Epoetin alfa was well tolerated. CONCLUSION Epoetin alfa is effective in improving the functional status and quality of life in anemic cancer patients receiving chemotherapy, as well as increasing hemoglobin level and decreasing transfusion requirements. Improvement in functional status can be attributed to an increase in hemoglobin level, demonstrating that quality of life in this group of patients can be improved by aggressively treating anemia. Further studies will be required to define the optimal doses and schedules for epoetin alfa.

Celiac plexus radiosurgery for pain management in advanced cancer patients: An international phase II trial.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. TPS466-TPS466
Author(s):  
Yaacov Richard Lawrence ◽  
Tikva Meron ◽  
Adam P. Dicker ◽  
Camilla Zimmermann ◽  
Maoz Ben-Ayun ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pancreatic Cancer ◽  
Clinical Trial ◽  
Cancer Patients ◽  
Short Form ◽  
Pilot Trial ◽  
Celiac Plexus ◽  
High Dose ◽  
Analgesic Use

TPS466 Background: Many cancer patients, especially those with pancreatic cancer, suffer from severe back/epigastric pain. Contemporary approaches (opioids, celiac blocks, systemic chemotherapy) are often inadequate. This clinical trial investigates a new approach in which high-dose radiation (radiosurgery) is focused on the retroperitoneal celiac plexus nerve bundle. Preliminary results from a single institution pilot trial NCT02356406 are promising: pain relief is substantial and side effects minimal. The main aim of the trial is to establish safety/efficacy in the setting of an international multicenter study. Exploratory analyses will examine the relationship between pain reduction and subjects’ quality-of-life, functionality, and caregiver burden. Methods: Eligibility criteria include a diagnosis of metastatic/unresectable malignancy, uncontrolled pain defined as ≥ 5 on 11-point BPI-SF scale despite analgesic use, typical retroperitoneal pain syndrome, prognosis > 8 weeks, ECOG 0-2, anatomical involvement of the celiac plexus (e.g. any pancreatic cancer, or any other cancer involving the celiac trunk). Exclusion criteria include previous upper abdo. radiation. The intervention consists of a single 25 Gy radiation fraction delivered to the celiac plexus, using anterolateral aspect of the aorta from the 12th thoracic to 2nd lumbar vertebral body as a surrogate structure. The primary tumour may be irradiated at physicians’ discretion. Dose-painting technique limits dose to organs at risk. Pain intensity will be measured using Brief Pain Inventory Short Form (BPI-SF), and quality of life with FACT-Hep. The primary endpoint is complete or partial pain response, defined as a decrease between the score immediately before treatment and 3 weeks’ post-treatment. A change of two or more on the BPI 11-point pain scale is defined as clinically significant. Secondary endpoints include other BPI pain endpoints, pain at 6 weeks, analgesic use, toxicity (CTCAE v4.03), quality of life and functional measures. Analgesia is not restricted. Expected accrual is 100 subjects over three years. Supported by Gateway for Cancer Research, additional support from Israel Cancer Association. Clinical trial information: NCT03323489.

Sign in / Sign up

Export Citation Format

Share Document